Antigens, CD

3 trials

Sponsors

Center of Molecular Immunology (CIM)

Conditions

Moderate-to-Severe Psoriasis PsoriasisRheumatoid Arthritis

Phase 1

Toxicological evaluation of the humanized Anti-CD6 MAb T1h in Rheumatoid Arthritis Patients

Active, not recruitingRPCEC00000007

Center of Molecular Immunology (CIM)Rheumatoid Arthritis

Start: 2004-07-30Target: 15Updated: 2026-09-14

Phase 2

Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid Arthritis

Active, not recruitingRPCEC00000035

Center of Molecular Immunology (CIM)Rheumatoid Arthritis

Start: 2008-01-14Updated: 2026-09-14

Phase 3

Itolizumab for Moderate-to-Severe Psoriasis-phase 3

Active, not recruitingRPCEC00000201

Center of Molecular Immunology (CIM)Moderate-to-Severe Psoriasis Psoriasis

Start: 2015-10-15Target: 144Updated: 2026-09-14